Refine
Has Fulltext
- yes (194)
Is part of the Bibliography
- yes (194)
Year of publication
Document Type
- Journal article (173)
- Conference Proceeding (8)
- Doctoral Thesis (7)
- Preprint (6)
Language
- English (194) (remove)
Keywords
- PET (29)
- positron emission tomography (25)
- Positronen-Emissions-Tomografie (21)
- prostate cancer (19)
- theranostics (15)
- CXCR4 (13)
- PET/CT (13)
- PRRT (11)
- PSMA (11)
- SPECT (11)
- multiple myeloma (10)
- neuroendocrine tumor (9)
- dosimetry (8)
- molecular imaging (8)
- radioligand therapy (8)
- SSTR (6)
- 18F-FDG (5)
- 53BP1 (5)
- RADS (5)
- chemokine receptor (5)
- prostate-specific membrane antigen (5)
- somatostatin receptor (5)
- FDG (4)
- NET (4)
- PSMA-RADS (4)
- Parkinson’s disease (4)
- biokinetics (4)
- inflammation (4)
- lymphoma (4)
- medicine (4)
- norepinephrine transporter (4)
- sympathetic nervous system (4)
- γ-H2AX (4)
- 18F-DCFPyL (3)
- 18F-FDG PET/CT (3)
- 18F-LMI1195 (3)
- DaTscan (3)
- MIBG (3)
- MRI (3)
- Prostate Cancer (3)
- SPECT/CT (3)
- Thyroid cancer (3)
- adrenocortical carcinoma (3)
- ageing (3)
- cardiac (3)
- dopamine (3)
- imaging (3)
- machine learning (3)
- peptide receptor radionuclide therapy (3)
- prognosis (3)
- prostate-specific membrane antigen (PSMA) (3)
- radioiodine therapy (3)
- radionuclide therapy (3)
- radiotherapy (3)
- reporting and data system (3)
- salvage radiotherapy (3)
- vandetanib (3)
- 11C-HED (2)
- 123I-mIBG (2)
- 123I-metaiodobenzylguanidine (2)
- 177Lu (2)
- 18F-FDS (2)
- Biokinetics (2)
- C-X-C motif chemokine receptor 4 (2)
- DNA damage (2)
- DNA repair (2)
- DOTATOC (2)
- Dosimetry (2)
- FDG PET/CT (2)
- Ioflupane (2)
- MAG3 (2)
- Myokarditis (2)
- Neuroendocrine Tumor (2)
- Oncology (2)
- PSMA I&T (2)
- PSMA-PET (2)
- Parkinson (2)
- Parkinson Disease (2)
- Parkinson's disease (2)
- Parkinson-Krankheit (2)
- Positron Emission Tomography (2)
- Positron emission tomography (2)
- Radionuclide Therapy (2)
- SSTR-RADS (2)
- SUV (2)
- Schilddrüsenkrebs (2)
- Stammzelle (2)
- TKI (2)
- Virchow Node (2)
- [177Lu]-DOTATATE/-DOTATOC (2)
- [68Ga] (2)
- [68Ga]PentixaFor (2)
- antidepressant (2)
- biodosimetry (2)
- biomarkers (2)
- bone disease (2)
- brain (2)
- cancer (2)
- cancer treatment (2)
- cardiac innervation imaging (2)
- cardiac nerve (2)
- cardiomyocytes (2)
- children (2)
- diabetes (2)
- diabetic cardiomyopathy (2)
- endoradiotherapy (2)
- fatty acid (2)
- fibroblast activation protein (2)
- follow-up (2)
- glioblastoma multiforme (2)
- guidelines (2)
- heart (2)
- heart failure (2)
- hiPSC-CM (2)
- immunohistochemistry (2)
- in vivo imaging (2)
- induced pluripotent stem cells (2)
- involvement (2)
- isotopes (2)
- kidney (2)
- magnetic resonance imaging (2)
- management (2)
- medullary thyroid carcinoma (2)
- metabolism (2)
- molecular medicine (2)
- myocardial sympathetic innervation imaging (2)
- myocarditis (2)
- nuclear medicine (2)
- personalized medicine (2)
- personalized treatment (2)
- positron emission tomography/computed tomography (2)
- precision medicine (2)
- radial (2)
- radiopharmaceuticals (2)
- relapse (2)
- repair (2)
- risk (2)
- sarcoidosis (2)
- somatostatin receptor (SSTR) (2)
- stem cell therapy (2)
- survival (2)
- thyroid cancer (2)
- tracer (2)
- tumor heterogeneity (2)
- tyrosine kinase inhibitor (2)
- 11C-Hydroxyephedrine (1)
- 11C-Methionine PET/CT (1)
- 11C-hydroxyephedrine (1)
- 123I-Ioflupane (1)
- 177Lu SPECT/CT imaging (1)
- 177Lu-DOTATATE (1)
- 177Lu-DOTATOC (1)
- 18-F-fluorothymidine uptake (1)
- 18F-DCFPL (1)
- 18F-flurpiridaz (1)
- 18FFBnTP (1)
- 1st International Workshop (1)
- 2- deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- 2-deoxy-2-18F-fluoro-D-sorbitol (1)
- 2015 (1)
- 223Ra (1)
- 224Ra (1)
- 3D printing (1)
- 5-Fluorouracil (1)
- 5IA-SPECT (1)
- 68Ga-DOTANOC (1)
- 68Ga-DOTATATE (1)
- 68Ga-DOTATATE/-TOC (1)
- 68Ga-DOTATOC (1)
- 68Ga-PSMA ligand PET/CT (1)
- 68Ga-Pentixafor PET/CT (1)
- 99mTc-DTPA (1)
- <sup>18</sup>F-FDG (1)
- <sup>68</sup>Ga-Pentixafor (1)
- AI (1)
- Ablation <Medizin> (1)
- Absorbed Doses (1)
- Administered Activities (1)
- Alzheimer’s disease (1)
- American Thyroid Association (1)
- Antibodies (1)
- Antidepressants (1)
- Arginine (1)
- B-cell lymphoma (1)
- BON-1 (1)
- BRAF mutation (1)
- BRAF(V600E) mutation (1)
- BSS directive (1)
- C-11-methionine pet (1)
- CD38 (1)
- CNS cancer (1)
- COVID-19 (1)
- CTCAE (1)
- CTNNB1 (1)
- CXCR4-targeting (1)
- CXCR4/SDF-1 (1)
- CXCR7 (1)
- CYP11B enzymes (1)
- Capicua transcriptional repressor (1)
- Carbon-11 (1)
- Cardiology (1)
- Cardiovascular diseases (1)
- Central venous access (1)
- Chernobyl (1)
- Conjugate arc therapy (1)
- Cushing’s disease (1)
- Cushing’s syndrome (1)
- DCGAN (1)
- DLBCL (1)
- DNA Breaks (1)
- DNA Damage Repair (1)
- DNA double-strand breaks (1)
- DOPA-responsive-dystonia (1)
- DOTA-EB-TATE (1)
- DSB damage (1)
- DSB focus substructure (1)
- DWI (1)
- DYT1 (1)
- Deep learning (1)
- Denoising (1)
- Diagnostic Imaging Exams (1)
- Diagnostic radiopharmaceuticals (1)
- Drug resistance (1)
- Dystonia (1)
- EANM (1)
- EANM dosage card (1)
- ECG (1)
- ECG-gated PET (1)
- Effective dose (1)
- Extramedullary disease (1)
- Extraocular eye muscles (1)
- F-18-FDG PET (1)
- FAP (1)
- FAPI PET/CT (1)
- FDG-PET (1)
- FDG-PET/CT (1)
- FDG-PET/MRI (1)
- FLT-PET (1)
- FV45 (1)
- Fabry Disease (FD) (1)
- GAN (1)
- GCA (1)
- GCH1 (1)
- GI (1)
- Ga-68 (1)
- Ga-68-labelled Peptides (1)
- Ganglia (1)
- Gastrointestinal (1)
- Gb3 and lyso-Gb3 biomarkers (1)
- German population (1)
- Gleason score (1)
- Glomerular filtration (1)
- HFmrEF (1)
- HFpEF (1)
- HMDP hydroxymethylene diphosphonate (1)
- Hamburg (1)
- Heart failure (1)
- Herz (1)
- Hickman catheter (1)
- Highlights Lecture (1)
- Hodgkin-lymphoma (1)
- Hyperkalaemia (1)
- I-131 ablation (1)
- IBA-1 (1)
- ICD (1)
- Image Quality (1)
- Imaging pitfalls (1)
- JR11 (1)
- Journal of Nuclear Cardiology (1)
- KWIC (1)
- Knochendichte (1)
- Knochenstoffwechsel (1)
- Langfristige Prognose (1)
- Levothyroxine (1)
- Lu-177 (1)
- Lutetium (1)
- Lysine (1)
- MDD (1)
- MI-RADS (1)
- MIBG scintigraphy (1)
- MOR202 (1)
- MPI (1)
- MS-18 (1)
- Magnetresonanztomografie (1)
- Matlab (1)
- Medullärer Schilddrüsenkrebs (1)
- Merkel cell carcinoma (1)
- Metaiodobenzylguanidine (1)
- Metastases (1)
- Micronuclei (1)
- Molecular Imaging (1)
- Molecular imaging (1)
- Molekulare Bildgebung (1)
- Monte Carlo (1)
- Multiple myeloma (1)
- Muskelkraft (1)
- Myeloma cells (1)
- Myelomas (1)
- Myocardial perfusion (1)
- Myocardial-perfusion SPECT (1)
- NEC (1)
- NR3C1 (1)
- NVP-BGT226 (1)
- Neuroendocrine (1)
- Neurosciences (1)
- Nierenfunktionsstörung (1)
- Nuclear Medicine (1)
- OPS201 (1)
- OXPHOS (1)
- P-glycoprotein expression (1)
- PET/MR systems (1)
- PMR (1)
- PROMISE (1)
- PSA (1)
- PSA response (1)
- PSMA PET/CT (1)
- PSMA-617 (1)
- PSMA-RADS-3A (1)
- PSMA-RADS-3B (1)
- PSMA-TV (1)
- PSMA-targeted PET (1)
- PSMA‐617 (1)
- Pancreas (1)
- Parkinson disease (1)
- Parkinsonism (1)
- Parkionson's disease (1)
- Pediatric Nuclear Medicine (1)
- Pediatric Patients (1)
- Pediatric malignancy (1)
- Pentixafor (1)
- Phase-II (1)
- Physics and instrumentation (1)
- Pitfall (1)
- Port (1)
- Positron-Emission Tomography (1)
- Positronenemissionstomografie (1)
- Preclinical evaluation (1)
- Primary hyperparathyroidism (pHPT) (1)
- Prostata (1)
- Prostate-cancer (1)
- QGP-1 (1)
- RLT (1)
- ROS (1)
- Ra-224 (1)
- Radiation Protection (1)
- Radiation-associated Cancer Risk (1)
- Radiofluorine (1)
- Radioiod (1)
- Radioiodine (1)
- Radioiodine Therapy (1)
- Radionuclide therapy (1)
- Radiopharmacy (1)
- Radiotracer (1)
- Radium (1)
- Raman micro-spectroscopy (1)
- Rhabdomyosarcoma (1)
- Risk Assessment (1)
- Rodents (1)
- SAH (1)
- SARS-CoV-2 (1)
- SPECT Scanner (1)
- SSTR-PET (1)
- Schilddrüse (1)
- Schilddrüsenhormontherapie (1)
- Simvastatin (1)
- Single Molecule Localization Microscopy (SMLM) (1)
- Single-Photon-Emissions-Computertomographie (1)
- Sodium-Glucose Cotransporters (SGLTs) (1)
- Somatostatin receptor expression (1)
- Standardisierung (1)
- T-Lymphozyten-Rezeptor (1)
- T-cell receptor assay (1)
- T-shaped π-π stacking (1)
- T-shaped π–π stacking (1)
- T1rho (1)
- T1ρ (1)
- TBI (1)
- TSPO (1)
- TT\(_{1rho}\) mapping (1)
- T\(_{1P}\) dispersion (1)
- T\(_{1P}\) mapping (1)
- Targeted therapy (1)
- Tc-99m-MAG3 Scans (1)
- Technetium Tc 99m Sestamibi Rats (1)
- Thrombosis (1)
- Thyroid carcinoma (1)
- Tracer (1)
- Transferrin-positive reticulocytes (1)
- USP28 (1)
- USP8 (1)
- WB-DW-MRI (1)
- Waldeyer’s tonsillar ring (1)
- Wnt (1)
- ZDF rats (1)
- [11C]-Choline PET/CT (1)
- [11C]-Methionine (1)
- [177Lu]/[90Y]PentixaTher (1)
- [177Lu]Lu-PSMA I&T (1)
- [177Lu]PentixaTher (1)
- [18F]FDG PET/CT (1)
- [18F]FDG-PET-CT (1)
- [18F]Fluorodeoxythymidine (1)
- [68Ga]DOTATOC (1)
- [68Ga]Pentixafor (1)
- [90Y]PentixaTher (1)
- [99mTc]-Sestamibi scan (1)
- [\(^{223}\)Ra]RaCl\(_{2}\) (1)
- [\(^{68}\)Ga] Pentixafor (1)
- [\(^{68}\)Ga] pentixafor (1)
- [\(^{68}\)Ga]Ga-FAPI (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{11}\)C-Methionine-PET (1)
- \(^{11}\)C-methionine (1)
- \(^{177}\)Lu (1)
- \(^{177}\)Lu-OPS201 (1)
- \(^{18}\)F (1)
- \(^{18}\)F-DCFPyL PET/CT (1)
- \(^{18}\)F-FDG (1)
- \(^{18}\)F-FDG PET/CT (1)
- \(^{18}\)F-PSMA-1007 (1)
- \(^{18}\)F-fluorodeoxyglucose (1)
- \(^{68}\)Ga (1)
- \(^{68}\)Ga-Pentixafor (1)
- \(^{99m}\)Tc-MAG3 (1)
- abdominal lymph node metastases (1)
- absorbed dose (1)
- absorbed dose to the blood (1)
- accuracy (1)
- acute myeloid leukemia (1)
- acute renal failure (1)
- adenocarcinoma of the lung (1)
- adrenal incidentaloma (1)
- adrenocortical (1)
- adsorption (1)
- advanced stages (1)
- agreement (1)
- alpha particles (1)
- alpha-emitters (1)
- amino acids (1)
- amyloid-β (Aβ) (1)
- analysis (1)
- androgen deprivation therapy (1)
- angiogenesis (1)
- angiotensin II type 1 receptor (1)
- antagonist (1)
- anthropometric measurements (1)
- antidepressants (1)
- areas (1)
- arrhythmia (1)
- artificial intelligence (1)
- association (1)
- attention deficit/hyperactivity disorder (ADHD) (1)
- autoimmune thyroiditis (1)
- autologous transplantation (1)
- autonomic nervous system (1)
- autoradiography (1)
- basal ganglia (1)
- base of support (1)
- benzylguanidine (1)
- beta oscillations (1)
- biological dosimetry (1)
- biomarker (1)
- biosynthesis (1)
- blood (1)
- blood flow (1)
- bone marrow cells (1)
- bone metabolism (1)
- bone mineral density (1)
- bone-marrow (1)
- bone-targeting radiopharmaceuticals (1)
- brain metabolic alterations (1)
- brain tumors (1)
- breast cancer (1)
- buparlisib (1)
- butyrylcholinesterase (1)
- c-MYC (1)
- calcitonin (1)
- cancer associated fibroblasts (1)
- cancer of unknown primary (CUP) (1)
- cancer-associated fibroblast (1)
- carbamate (1)
- carboxylation (1)
- carcinoma (1)
- carcinoma metastases to pancreas (1)
- cardiac neurohormonal system (1)
- cardiac sympathetic nerve system (1)
- cardiac sympathetic nervous system (1)
- cardioprotective potential (1)
- cardiovascular diseases (1)
- caudate nucleus (1)
- cell biology (1)
- cell staining (1)
- cells (1)
- cerebral gliomas (1)
- chemokine receptor-4 (1)
- childhood and adolescence (1)
- cholinergic activity (1)
- chromatin mobility (1)
- clinical diagnosis (1)
- coefficient (1)
- cognitive decline (1)
- coherence analysis (1)
- coherent anti-Stokes Raman scattering (CARS) microscopy (1)
- collagens (1)
- collimator (1)
- combination (1)
- comparability (1)
- complex DNA damage (1)
- computational biology and bioinformatics (1)
- contractility (1)
- contrast agent (1)
- coronary artery disease (1)
- correction (1)
- criteria (1)
- damage (1)
- daratumumab (1)
- data analysis (1)
- delineation (1)
- dementia (1)
- depression (1)
- detection rate (1)
- diagnostic medical radiation exposure (1)
- diagnostics (1)
- diastolic dysfunction (1)
- differentiated thyroid cancer (1)
- differentiated thyroid carcinoma (1)
- diffuse (1)
- diffusion weighted MRI (1)
- diffusion weighted mri (1)
- dilated cardiomyopathy with ataxia (1)
- disease (1)
- dissection (1)
- distant metastases (1)
- dopamine acetylcholine (1)
- dopamine transporter (DAT) (1)
- dose response (1)
- double-stranded (1)
- drug discovery (1)
- early response (1)
- editorial (1)
- ejection fraction (1)
- endocrinology (1)
- enzyme kinetics (1)
- epidemiology (1)
- esophagogastric junction (1)
- evans blue (1)
- exome sequencing (1)
- experience (1)
- exposure (1)
- extracellular matrix (1)
- extramedullary hematopoiesis (1)
- flare phenomenon (1)
- fluorine-18 (1)
- focal (1)
- focused surgical approach (1)
- folinic acid (1)
- follicular lymphoma (1)
- free‐breathing (1)
- gait initiation (1)
- gamma rays (1)
- gefitinib (1)
- gemcitabine (1)
- genetics (1)
- giant cell arteritis (1)
- glioblastoma (1)
- glioma (1)
- glomerular filtration rate (1)
- glucocorticoid excess (1)
- harmonization of SPECT/CT imaging (1)
- head and neck cancer (1)
- health care (1)
- healthy volunteers (1)
- heart failure with mid-range ejection fraction (1)
- heart-to-mediastinum ratio (1)
- hematotoxicity (1)
- heptacellular carcinoma (1)
- high LET irradiation (1)
- high risk (1)
- histone H2AX (1)
- humans (1)
- hydroxyephedrine (1)
- hypercortisolism (1)
- hyperkalemia (1)
- hypothyroidism (1)
- imaging proliferation (1)
- imaging techniques (1)
- immune check inhibitor (1)
- immune infiltration (1)
- immunostaining (1)
- improves (1)
- in vivo formation (1)
- in-vivo (1)
- inhibition (1)
- initial experience (1)
- international multicenter comparison exercise (1)
- interobserver (1)
- interreader (1)
- intraindividual comparison (1)
- iodine contrast (1)
- iodine nutrition (1)
- iodine-131 (1)
- irinotecan (1)
- irradiation (1)
- isotopic labelling (1)
- kidney function (1)
- kinase inhibitor (1)
- late response (1)
- left-ventricular function (1)
- lesions (1)
- leukocytes (1)
- levodopa-induced dyskinesia (1)
- linear conversion (1)
- locally advanced disease (1)
- long-term complications (1)
- long-term outcome (1)
- lung (1)
- lung and intrathoracic tumors (1)
- lung cancer (1)
- lutetium-177 (1)
- mIBG (1)
- mRNA (1)
- macrophages (1)
- macroscopic recurrence (1)
- major depressive disorder (1)
- malignancies (1)
- malignant lymphoma (1)
- mammalian target of rapamycin (1)
- mapping (1)
- matched pair (1)
- mechanisms retention (1)
- medium-sized animals (1)
- medullary thyroid cancer (1)
- meningioma (1)
- metabolic tumor volume (MTV) (1)
- metabolic tumour volume (MTV) (1)
- metastasis-directed therapy (1)
- methionine (1)
- methionine pet (1)
- methylation (1)
- methylphenidate (1)
- miRNA (1)
- mice (1)
- microenvironment (1)
- microglial cells (1)
- mitochondria (1)
- molecular biology (1)
- molecular diagnostics (1)
- molecular radiotherapy (1)
- molecular radiotherapy (MRT) (1)
- motor control (1)
- mouse (1)
- movement disorders (1)
- moycardial sympathetic innervation (1)
- multi-pinhole collimation (1)
- multiple system atrophy (1)
- multivariate data analysis (1)
- muscle force (1)
- myocardial nerve (1)
- myocardial perfusion imaging (1)
- nab-paclitaxel (1)
- neoadjuvant chemotherapy (1)
- nephrology (1)
- nephrotoxicity (1)
- neuroblastoma (1)
- neuroendocrine neoplasia (1)
- neuroendocrine neoplasms (NEN) (1)
- neuroendocrine tumor (NET) (1)
- neuroendocrine tumors (1)
- neuroendocrine tumors (NET) (1)
- neuroinflammation (1)
- neurology (1)
- nicotinic receptors (1)
- nitrate and thyroid carcinogenesis (1)
- non-Hodgkin's lymphoma (1)
- non-hodgkins-lymphoma (1)
- nonhuman primates (1)
- nuclear cardiology (1)
- nuclear medicine therapy (1)
- oligorecurrence (1)
- ollimator (1)
- optimization (1)
- organic cation transporter (1)
- osteoporosis (1)
- other radiation exposure (atomic bombing/nuclear accidents) (1)
- outcomes research (1)
- overall survival (1)
- oxaliplatin (1)
- pancreas (1)
- pancreatic cancer (1)
- papillary (1)
- papillary thyroid carcinoma (PTC) (1)
- parathyroid adenoma (1)
- parathyroid carcinoma (1)
- pattern (1)
- pediatric patients (1)
- pediatric thyroid cancer after Chernobyl and Fukushima (1)
- pembrolizumab (1)
- peptide receptor (1)
- performance (1)
- performance evaluation (1)
- peripheral injury (1)
- peripheral nervous system (1)
- phaeochromocytoma (1)
- phantom (1)
- phenethylguanidine (1)
- phosphatidylinositol-3-kinase (1)
- phosphorylation (1)
- photons (1)
- pig model (1)
- pleural mesothelioma (1)
- polymyalgia rheumatica (1)
- pooled (1)
- positron-emission-tomography (1)
- post-reconstruction filtering (1)
- power-station accident (1)
- preclinical PET (1)
- preclinical imaging (1)
- prediction (1)
- preoperative localization (1)
- primary hyperparathyroidism (1)
- prognostic value (1)
- progression (1)
- prostate-specific antigen (1)
- pulmonary imaging (1)
- quality (1)
- quantification (1)
- quantitative MRI (1)
- quantitative SPECT/CT (1)
- quantitative imaging (1)
- radiation (1)
- radiation effects (1)
- radiobiology (1)
- radiochemistry (1)
- radiogenomics (1)
- radioiodine (1)
- radiotracer (1)
- radiotracer kinetics (1)
- radiotracers (1)
- radium (1)
- rats (1)
- recurrence (1)
- recurrent prostate cancer (1)
- refractory (1)
- renal (1)
- renal failure (1)
- renal function (1)
- renal imaging (1)
- renal scintigraphy (1)
- renin-angiotensin system (1)
- repeat surgery (1)
- repeated surgery (1)
- reporting and data systems (1)
- response evaluation (1)
- responsivity (1)
- rising incidence of thyroid cancer (1)
- risk assessment (1)
- scanner (1)
- screening and overdiagnosis (1)
- second hit (1)
- second primary malignancy (1)
- secondary lung tumors (1)
- self‐gated (1)
- selpercatinib (1)
- sepsis (1)
- sigma-1 receptor-directed molecular imaging (1)
- signal to noise ratio (1)
- signaling pathway (1)
- simultaneous integrated boost (1)
- single photon emission computed tomography (SPECT) (1)
- single photon emission computed tomography: sympathetic nerve (1)
- skeletal (1)
- skin biopsy (1)
- skin hemagioma (1)
- small animal (1)
- small animal SPECT (1)
- small-animal SPECT (1)
- small-animal imaging (1)
- smoldering myeloma (1)
- software (1)
- solid tumors (1)
- somatostatin (1)
- somatostatin receptors (1)
- sorbents (1)
- spin lock (1)
- spin-lock (1)
- spleen (1)
- split renal function (1)
- staging (1)
- standardization (1)
- standardization of SPECT/CT imaging (1)
- standardized reporting (1)
- standardized reporting system (1)
- statin (1)
- stem cells (1)
- stem-cell research (1)
- stem-cell transplantation (1)
- stimulation (1)
- storage vesicle turnover (1)
- striatum (1)
- stroke (1)
- structure–activity relationships (1)
- subthalamic nucleus (1)
- super ultraviolet (1)
- surgery (1)
- surgical treatment (1)
- sympathetic nerve (1)
- target (1)
- taxane (1)
- therapeutic medical radiation exposure (EBRT/ RAI) (1)
- therapeutic target (1)
- thyroid (1)
- thyroid carcinoma (TC) (1)
- thyroid carcinomas (1)
- total lesion PSMA (1)
- total lesion glycolysis (TLG) (1)
- total lesion methionine uptake (TLMU) (1)
- traceability of SPECT/CT imaging (1)
- trachea (1)
- transcriptome (1)
- treatment (1)
- treatment response (1)
- trial (1)
- tumor (1)
- tumor burden (1)
- tumor microenvironment (1)
- unilateral ureteral obstruction (1)
- urology (1)
- valsartan (1)
- various cancer diseases (1)
- vasculature (1)
- vasculitis (1)
- vemurafenib (1)
- vestibular schwannoma (1)
- wave‐CAIPI (1)
- weight drop (1)
- whole body MRI (1)
- whole-body (1)
- young females (1)
- α-Emitter (1)
- α-Particle (1)
- α-emitter (1)
- β-catenin (1)
- γ-h2ax (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (194) (remove)
Sonstige beteiligte Institutionen
- Johns Hopkins School of Medicine (17)
- Johns Hopkins University School of Medicine (5)
- Johns Hopkins School of Medicine, Baltimore, MD, U.S. (4)
- Department of Biomedical Imaging, National Cerebral and Cardiovascular Research Center, Suita, Japan (2)
- Division of Medical Technology and Science, Department of Medical Physics and Engineering, Course of Health Science, Osaka University Graduate School of Medicine, Suita Japan (2)
- Institut for Molecular Biology and CMBI, Department of Genomics, Stem Cell Biology and Regenerative Medicine, Leopold-Franzens-University Innsbruck, Innsbruck, Austria (2)
- Johns Hopkins School of Medicine, The Russell H Morgan Department of Radiology and Radiological Science, Baltimore, MD, USA (2)
- Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, Munich, Germany (1)
- CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - the development agency of the Brazilian Federal Government (1)
- DAAD - Deutscher Akademischer Austauschdienst (1)
Background
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. Tumor-associated macrophages (TAM) have been shown to promote malignant growth and to correlate with poor prognosis. [1,4,7,10-tetraazacyclododecane-NN′,N″,N′″-tetraacetic acid]-d-Phe1,Tyr3-octreotate (DOTATATE) labeled with Gallium-68 selectively binds to somatostatin receptor 2A (SSTR2A) which is specifically expressed and up-regulated in activated macrophages. On the other hand, the role of SSTR2A expression on the cell surface of glioma cells has not been fully elucidated yet. The aim of this study was to non-invasively assess SSTR2A expression of both glioma cells as well as macrophages in GBM.
Methods
15 samples of patient-derived GBM were stained immunohistochemically for macrophage infiltration (CD68), proliferative activity (Ki67) as well as expression of SSTR2A. Anti-CD45 staining was performed to distinguish between resident microglia and tumor-infiltrating macrophages. In a subcohort, positron emission tomography (PET) imaging using \(^{68}Ga-DOTATATE\) was performed and the semiquantitatively evaluated tracer uptake was compared to the results of immunohistochemistry.
Results
The amount of microglia/macrophages ranged from <10% to >50% in the tumor samples with the vast majority being resident microglial cells. A strong SSTR2A immunostaining was observed in endothelial cells of proliferating vessels, in neurons and neuropile. Only faint immunostaining was identified on isolated microglial and tumor cells. Somatostatin receptor imaging revealed areas of increased tracer accumulation in every patient. However, retention of the tracer did not correlate with immunohistochemical staining patterns.
Conclusion
SSTR2A seems not to be overexpressed in GBM samples tested, neither on the cell surface of resident microglia or infiltrating macrophages, nor on the surface of tumor cells. These data suggest that somatostatin receptor directed imaging and treatment strategies are less promising in GBM.
Purpose
For somatostatin receptor (SSTR)-positron emission tomography/computed tomography (PET/CT), a standardized framework termed SSTR-reporting and data system (RADS) has been proposed. We aimed to elucidate the impact of a RADS-focused training on reader’s anxiety to report on SSTR-PET/CT, the motivational beliefs in learning such a system, whether it increases reader’s confidence, and its implementation in clinical routine.
Procedures
A 3-day training course focusing on SSTR-RADS was conducted. Self-report questionnaires were handed out prior to the course (Pre) and thereafter (Post). The impact of the training on the following categories was evaluated: (1) test anxiety to report on SSTR-PET/CT, (2) motivational beliefs, (3) increase in reader’s confidence, and (4) clinical implementation. To assess the effect size of the course, Cohen’s d was calculated (small, d = 0.20; large effect, d = 0.80).
Results
Of 22 participants, Pre and Post were returned by 21/22 (95.5%). In total, 14/21 (66.7%) were considered inexperienced (IR, < 1 year experience in reading SSTR-PET/CTs) and 7/21 (33.3%) as experienced readers (ER, > 1 year). Applying SSTR-RADS, a large decrease in anxiety to report on SSTR-PET/CT was noted for IR (d = − 0.74, P = 0.02), but not for ER (d = 0.11, P = 0.78). For the other three categories motivational beliefs, reader’s confidence, and clinical implementation, agreement rates were already high prior to the training and persisted throughout the course (P ≥ 0.21).
Conclusions
A framework-focused reader training can reduce anxiety to report on SSTR-PET/CTs, in particular for inexperienced readers. This may allow for a more widespread adoption of this system, e.g., in multicenter trials for better intra- and interindividual comparison of scan results.
Isolated generalized dystonia is a central motor network disorder characterized by twisted movements or postures. The most frequent genetic cause is a GAG deletion in the Tor1a (DYT1) gene encoding torsinA with a reduced penetrance of 30-40 % suggesting additional genetic or environmental modifiers. Development of dystonia-like movements after a standardized peripheral nerve crush lesion in wild type (wt) and Tor1a+/- mice, that express 50 % torsinA only, was assessed by scoring of hindlimb movements during tail suspension, by rotarod testing and by computer-assisted gait analysis. Western blot analysis was performed for dopamine transporter (DAT), D1 and D2 receptors from striatal and quantitative RT-PCR analysis for DAT from midbrain dissections. Autoradiography was used to assess the functional DAT binding in striatum. Striatal dopamine and its metabolites were analyzed by high performance liquid chromatography. After nerve crush injury, we found abnormal posturing in the lesioned hindlimb of both mutant and wt mice indicating the profound influence of the nerve lesion (15x vs. 12x relative to control) resembling human peripheral pseudodystonia. In mutant mice the phenotypic abnormalities were increased by about 40 % (p < 0.05). This was accompanied by complex alterations of striatal dopamine homeostasis. Pharmacological blockade of dopamine synthesis reduced severity of dystonia-like movements, whereas treatment with L-Dopa aggravated these but only in mutant mice suggesting a DYT1 related central component relevant to the development of abnormal involuntary movements. Our findings suggest that upon peripheral nerve injury reduced torsinA concentration and environmental stressors may act in concert in causing the central motor network dysfunction of DYT1 dystonia.
Tyrosine kinase inhibitors (TKI) have shown clinical effectiveness in iodine-refractory differentiated thyroid cancer (DTC). The corresponding role of serum thyroglobulin (Tg) in iodine-refractory DTC has not been investigated yet. 9 patients (3 female, 61 ± 8y) with progressive iodine-refractory DTC starting on lenvatinib were considered. Tumor restaging was performed every 2–3 months including contrast-enhanced computed tomography (CT, RECIST 1.1). Serum Tg was measured and compared to imaging findings. After treatment initiation, serum Tg levels dropped in all patients with a median reduction of 86.2%. During long-term follow-up (median, 25.2 months), fluctuations in Tg could be observed in 8/9 subjects. According to RECIST, 6/9 subjects achieved a partial response or stable disease with the remaining 3/9 experiencing progressive disease (2/3 with Tg levels rising above baseline). All of the patients with disease progression presented with a preceding continuous rise in serum Tg, whereas tumor marker oscillations in the subjects with controlled disease were only intermittent. Initiation of lenvatinib in iodine-refractory DTC patients is associated with a significant reduction in serum Tg levels as a marker of treatment response. In the course of treatment, transient Tg oscillations are a frequent phenomenon that may not necessarily reflect morphologic tumor progression.
Background
Reliable central venous access (CVC) is essential for hematology–oncology patients since frequent puncture of peripheral veins—e.g., for chemotherapy, antibiotic administration, repeated blood sampling, and monitoring—can cause unacceptable pain and psychological trauma, as well as severe side effects in cases of extravasation of chemotherapy drugs. However, CVC lines still carry major risk factors, including thrombosis, infection (e.g., entry site, tunnel, and luminal infections), and catheter dislocation, leakage, or breakage.
Methods
Here we performed a retrospective database analysis to determine the incidence of CVC-associated thrombosis in a single-center cohort of 448 pediatric oncologic patients, and to analyze whether any subgroup of patients was at increased risk and thus might benefit from prophylactic anticoagulation.
Results
Of the 448 patients, 269 consecutive patients received a CVC, and 55 of these 269 patients (20%) also had a thrombosis. Of these 55 patients, 43 had at least one CVC-associated thrombosis (total number of CVC-associated thrombosis: n = 52). Among all patients, the median duration of CVC exposure was 464 days. Regarding exposure time, no significant difference was found between patients with and without CVC-associated thrombosis. Subclavia catheters and advanced tumor stages seem to be the main risk factors for the development of CVC-associated thrombosis, whereas pharmacologic prophylaxis did not seem to have a relevant impact on the rate of thrombosis.
Conclusions
We conclude that pediatric surgeons and oncologists should pay close attention to ensuring optimal and accurate CVC placement, as this appears the most effective tool to minimize CVC-associated complications.
Purpose of Review
Statins are routinely applied in patients with coronary artery disease, as they allow significantly to reduce blood cholesterol levels. Although those drugs are endorsed by current guidelines and prescribed routinely, a substantial portion of patients are still statin-intolerant and image-piloted strategies may then be helpful to identify patients that need further intensified treatment, e.g., to initiate treatment with proprotein convertase subtilisin / kexin type 9 inhibitors (PCSK9i). In addition, it has also been advocated that statins exhibit nonlipid, cardio-protective effects including improved cardiac nerve integrity, blood flow, and anti-inflammatory effects in congestive heart failure (HF) patients.
Recent Findings
In subjects after myocardial infarction treated with statins, \(^{123}\)I-metaiodobenzylguanidine (MIBG) scintigraphy has already revealed enhanced cardiac nerve function relative to patients without statins. In addition, all of those aforementioned statin-targeted pathways in HF can be visualized and monitored using dedicated cardiac radiotracers, e.g., \(^{123}\)I-MIBG or \(^{18}\)F-AF78 (for cardiac nerve function), \(^{18}\)F-flurpiridaz (to determine coronary flow) or \(^{68}\)Ga-PentixaFor (to detect inflammation).
Summary
Statins exhibit various cardio-beneficial effects, including improvement of cardiac nerve function, blood flow, and reduction of inflammation, which can all be imaged using dedicated nuclear cardiac radiotracers. This may allow for in vivo monitoring of statin-induced cardioprotection beyond lipid profiling in HF patients.
Tracing its roots back to the 1940s, theranostics in nuclear oncology has proved successful mainly due to the beneficial effects of image-guided therapeutic concepts for patients afflicted with a variety of different cancers. The majority of these treatments are not only characterized by substantial prolongation of progression-free and overall survival, but are also generally safe, rendering theranostic agents as an attractive treatment option in various clinical scenarios in oncology. In this Special Issue Novel Theranostic Agents, nine original articles from around the globe provide further evidence on the use of the theranostic concept for neuroendocrine neoplasm (NEN), prostate cancer (PC), meningioma, and neuroblastoma. The investigated diagnostic and therapeutic radiotracers target not only established structures, such as somatostatin receptor, prostate-specific membrane antigen or norepinephrine transporter, but also recently emerging targets such as the C-X-C motif chemokine receptor 4. Moreover, the presented original articles also combine the concept of theranostics with in-depth read-out techniques such as radiomics or novel reconstruction algorithms on pretherapeutic scans, e.g., for outcome prediction. Even 80 years after its initial clinical introduction, theranostics in oncology continues to thrive, now more than ever.
Background:
Recent decades have seen a rise in the incidence of well-differentiated (mainly papillary) thyroid carcinoma around the world. In Germany, the age-adjusted incidence of well-differentiated thyroid carcinoma in 2010 was 3.5 per 100 000 men and 8.7 per 100 000 women per year.
Method:
This review is based on randomized, controlled trials and multicenter trials on the treatment of well-differentiated thyroid carcinoma that were retrieved by a selective literature search, as well as on three updated guidelines issued in the past two years.
Results:
The recommended extent of surgical resection depends on whether the tumor is classified as low-risk or high-risk, so that papillary microcar cinomas, which carry a highly favorable prognosis, will not be overtreated. More than 90% of localized, well-differentiated thyroid carcinomas can be cured with a combination of surgery and radioactive iodine therapy. Radio active iodine therapy is also effective in the treatment of well-differentiated thyroid carcinomas with distant metastases, yielding a 10-year survival rate of 90%, as long as there is good iodine uptake and the tumor goes into remission after treatment; otherwise, the 10-year survival rate is only 10%. In the past two years, better treatment options have become available for radioactive-iodine-resistant thyroid carcinoma. Phase 3 studies of two different tyrosine kinase inhibitors have shown that either one can markedly prolong progression-free survival, but not overall survival. Their more common clinically significant side effects are hand-foot syndrome, hypertension, diarrhea, proteinuria, and weight loss.
Conclusion:
Slow tumor growth, good resectability, and susceptibility to radioactive iodine therapy lend a favorable prognosis to most cases of well-differentiated thyroid carcinoma. The treatment should be risk-adjusted and interdisciplinary, in accordance with the current treatment guidelines. Even metastatic thyroid carcinoma has a favorable prognosis as long as there is good iodine uptake. The newly available medical treatment options for radioactive-iodine-resistant disease need to be further studied.
More than 25 years after the first peptide receptor radionuclide therapy (PRRT), the concept of somatostatin receptor (SSTR)-directed imaging and therapy for neuroendocrine tumors (NET) is seeing rapidly increasing use. To maximize the full potential of its theranostic promise, efforts in recent years have expanded recommendations in current guidelines and included the evaluation of novel theranostic radiotracers for imaging and treatment of NET. Moreover, the introduction of standardized reporting framework systems may harmonize PET reading, address pitfalls in interpreting SSTR-PET/CT scans and guide the treating physician in selecting PRRT candidates. Notably, the concept of PRRT has also been applied beyond oncology, e.g. for treatment of inflammatory conditions like sarcoidosis. Future perspectives may include the efficacy evaluation of PRRT compared to other common treatment options for NET, novel strategies for closer monitoring of potential side effects, the introduction of novel radiotracers with beneficial pharmacodynamic and kinetic properties or the use of supervised machine learning approaches for outcome prediction. This article reviews how the SSTR-directed theranostic concept is currently applied and also reflects on recent developments that hold promise for the future of theranostics in this context.
Objectives. This study is aimed at investigating the impact of frame numbers in preclinical electrocardiogram- (ECG-) gated \(^{18}\)F-fluorodeoxyglucose (\(^{18}\)F-FDG) positron emission tomography (PET) on systolic and diastolic left ventricular (LV) parameters in rats. Methods. \(^{18}\)F-FDG PET imaging using a dedicated small animal PET system with list mode data acquisition and continuous ECG recording was performed in diabetic and control rats. The list-mode data was sorted and reconstructed with different numbers of frames (4, 8, 12, and 16) per cardiac cycle into tomographic images. Using an automatic ventricular edge detection software, left ventricular (LV) functional parameters, including ejection fraction (EF), end-diastolic (EDV), and end-systolic volume (ESV), were calculated. Diastolic variables (time to peak filling (TPF), first third mean filling rate (1/3 FR), and peak filling rate (PFR)) were also assessed. Results. Significant differences in multiple parameters were observed among the reconstructions with different frames per cardiac cycle. EDV significantly increased by numbers of frames (353.8 & PLUSMN; 57.7 mu l*, 380.8 & PLUSMN; 57.2 mu l*, 398.0 & PLUSMN; 63.1 mu l*, and 444.8 & PLUSMN; 75.3 mu l at 4, 8, 12, and 16 frames, respectively; *P < 0.0001 vs. 16 frames), while systolic (EF) and diastolic (TPF, 1/3 FR and PFR) parameters were not significantly different between 12 and 16 frames. In addition, significant differences between diabetic and control animals in 1/3 FR and PFR in 16 frames per cardiac cycle were observed (P < 0.005), but not for 4, 8, and 12 frames. Conclusions. Using ECG-gated PET in rats, measurements of cardiac function are significantly affected by the frames per cardiac cycle. Therefore, if you are going to compare those functional parameters, a consistent number of frames should be used.